20th Conference on Retroviruses and Opportunistic Infections

Conference Reports for NATAP

20th Conference on Retroviruses and
Opportunistic Infections
Atlanta GA
March 3 - 6, 2013

SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders - (03/06/13)

Similar Cognition Outcomes After 24 Weeks for Tenofovir/FTC + Atazanavir/r (ATV/r)-Experienced HIV+ Subjects or Those Simplifying to Abacavir/3TC+ATV - (03/06/13)

High Efficacy of Sofosbuvir in Combination with Weight Based Ribavirin for 24 weeks in Difficult to Treat HCV Infected Genotype-1 Patients - (03/06/13)

Distribution and Antiviral Activity in Cerebrospinal Fluid (CSF) of the Integrase Inhibitor, Dolutegravir (DTG): ING116070 Week 16 Results - (03/06/13)

Dolutegravir (DTG) Versus Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: 24-Week Interim Results From SAILING (ING111762) - (03/06/13)

Baby Cure at CROI - (03/06/13)

NRTI-Sparing Second-Line Regimen Holds Its Own in Randomized Trial - written by Mark Mascolini - (03/06/13)

Peak Bone Mass Lower in Young HIV+ vs HIV- Men--and Bone Structure Abnormal - written by Mark Mascolini - (03/06/13)

Dolutegravir Superior to Raltegravir in ART-Experienced Integrase Inhibitor Naive at 24 Weeks - written by Mark Mascolini - (03/06/13)

Wide US Study Finds 16% With Newly Diagnosed HIV Carry Resistant Virus - written by Mark Mascolini - (03/06/13)

Safety and Antiviral Activity of MK-1439, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), In Treatment-Naïve HIV-Infected Patients - (03/05/13)

Seven-Day Monotherapy With New NNRTI Yields Sharp Viral Load Drop - written by Mark Mascolini - (03/05/13)

Smoking Rate Twice Higher With Than Without HIV in First National US Study - written by Mark Mascolini - (03/05/13)

Long-Term Efavirenz Linked to Worse Neurocognitive Function in US CHARTER Group - written by Mark Mascolini - (03/05/13)

Coronary Artery Danger Signals More Common in Young HIV+ Men Than HIV- Men - written by Mark Mascolini - (03/05/13)

Comparative Study of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate, Each with Elvitegravir, Cobicistat, and Emtricitabine, for HIV Treatment - (03/05/13)

New tenofovir prodrug virologically equivalent to TDF--and easier on kidneys and bone - written by Mark Mascolini - (03/05/13)

Protective Effect of HBV-active c-ART against primary HBV-Infection - (03/05/13)

Age Raises Rate of Dangerous Coronary Artery Plaques in HIV+ But Not HIV- MACS Men - written by Mark Mascolini - (03/05/13)

Higher MI, ESRD, Cancer Rates With HIV--But Not Necessarily at Younger Age - written by Mark Mascolini - (03/05/13)

Age Raises Rate of Dangerous Coronary Artery Plaques in HIV+ But Not HIV- MACS Men - written by Mark Mascolini - (03/05/13)

First interim results from a phase IIa study evaluating an all-oral regimen of Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients - press release - (03/04/13)

Was An Infant Cured Of HIV? - (03/04/13)

For First Time, Baby Is Cured of H.I.V., Doctors Say - (03/04/13)

Long-Acting Integrase Inhibitor Shields Macaques From Anal Simian HIV - written by Mark Mascolini - (03/04/13)


HIV Prevention Fails in All Three VOICE Arms, as Daily Truvada PrEP Falls - written by Mark Mascolini - (03/04/13)

"Functional Cure" of HIV Claimed for Baby Treated 30 Hours After Birth - written by Mark Mascolini - (03/04/13)

ELECTRON: 100% SVR Rate for Once-Daily Sofosbuvir Plus Ledipasvir Plus Ribavirin Given for 12 Weeks in Treatment-Naïve and Previously Treated Patients With HCV GT 1 - (03/04/13)

RISK OF VIROLOGIC RELAPSE IN HEPATITIS C, GENOTYPE 1-INFECTED SUBJECTS AFTER 8, 12, OR 24 WEEKS OF TREATMENT WITH ABT-450/r + ABT-267 + ABT-333 + RBV: IDENTIFYING OPTIMAL TREATMENT DURATION - (03/04/13)

12 WEEKS OF ABT-450/r, NON-NUCLEOSIDE INHIBITOR AND RBV ACHIEVED SVR24 IN >90% OF TREATMENT-NAIVE HCV GT1 PATIENTS AND 47% OF PRIOR NONRESPONDERS - (03/04/13)

Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers - (03/04/13)

STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV - (03/04/13)

Boerhinger Ingelheim Announes Interim Results Evaluating Virologic Response Rates in HCV/HIV Coinfected Patients Treated with HCV Protease BI201335, and Drug Drug Interaction Studies with HIV ARTs - (03/04/13)